Save Product
Product Details
- ProductSizeAmountActiveMax® Human CD22 μBeads, premium grade (for cells)2.5 mg2.5×10⁷ beadsActiveMax® Human CD22 μBeads, premium grade (for cells)10 mg (2.5 mg×4)1.0×10⁸ beads
Product Show
This product can be directly isolated using conventional column-free magnetic stand (eg. Cat. MB-01/ MB-02/ MB-03/ MB-04). Please note that due to its micron-scale size, it is not compatible with commercially available column-based (M/D/L) magnetic separation systems.
Product Description
ActiveMax® Human CD22 μBeads, premium grade (for cells) are uniform, superparamagnetic beads of 5.5 µm in diameter immobilized with Human CD22 protein expressed from human 293 cells (HEK293) and contains AA Asp 20 - Arg 687 (Accession # P20273-1).
ActiveMax® Human CD22 μBeads, premium grade (for cells) are produced under sterile manufacturing conditions (ISO 5), and no animal- or human-derived components are used throughout the production process. It is produced under our rigorous quality control system that includes a comprehensive set of tests including sterility and endotoxin tests.Application
ActiveMax® Human CD22 μBeads, premium grade (for cells) are designed to stimulate in vitro CD22-specific CAR-T cells or UCAR-T cells, similar to the tumor cell lines that express human CD22 antigen. It can be used as follows:
Evaluating the characteristics of CAR-T cells or UCAR-T cells.
In vitro expansion of CD22-specific CAR-T cells or UCAR-T cells.
In vitro enrichment of CD22-specific CAR-T cells or UCAR-T cells.Reconstitution
See Certificate of Analysis (CoA) for detailed instruction.
Storage
This product is stable in storage under the following conditions: -20˚C for 12 months in lyophilized state. -70°C for 3 months under sterile conditions after reconstitution.
Please protect from light and avoid repeated freeze-thaw cycles.Immediate use after reconstitution is highly recommended.
Sterility
Negative
Endotoxin
Less than 0.002 EU per μg by the LAL method / rFC method.
Mycoplasma
Negative
Important Note
This product is for research use only and not intended for therapeutic or in vivo diagnostic use.
Formulation
Lyophilized in PBS with 0.1% HSA，pH 7.4. Trehalose is added as protectant before lyophilization.
ACRO Quality Management System
Customers Also Viewed
Performance Data
FACS Data
Assay of human CD22 protein on the μBeads surface by Flow cytometry. ActiveMax® Human CD22 μBeads, premium grade (for cells) (Cat. No. MBS-C007) were stained with anti-human CD22 antibody, and then followed by FITC anti-human IgG Fc antibody and analyzed by flow cytometry.
Protocol
Assay of human CD22 protein on the μBeads surface by Flow cytometry. The human CD22 protein conjugated on the μBeads (Cat. No. MBS-C007) surface were fluorescently stained using Monoclonal Anti-Human CD22 Antibody and PE anti-human IgG Fc antibody, and analyzed by flow cytometry.
Protocol
Stimulate Siglec-2 CAR-T Cells -Cytokines
ActiveMax® Human CD22 μBeads, premium grade (for cells) (Cat. No. MBS-C007) can activate CD22-specific CAR-T cells by detecting the secretion of IFN- γ in vitro.
CD22 CAR-T cells were stimulated with ActiveMax® Human CD22 μBeads (Cat. No. MBS-C007) for 24 h , and cell-free supernatants were harvested for evaluating IFN-γ、TNF-α、IL-4、IL-6 secretion by flow cytometry. The results showed that CD22 CAR-T cells released significantly larger amounts of IFN-γ、TNF-α、IL-4、IL-6 into the supernatants in response to CD22 μBeads (Data is the average of 3 independent experiments, error bars ± SD).
Stimulate Siglec-2 CAR-T Cells -Cytotoxic Molecules
CD22 CAR-T cells were stimulated with ActiveMax® Human CD22 μBeads (Cat. No. MBS-C007) for 24h, and cell-free supernatants were harvested for evaluating Granzyme B secretion by ELISA. The results showed that CD22 CAR-T cells released significantly larger amounts of Granzyme B into the supernatants in response to CD22 μBeads (Data is the average of 3 independent experiments, error bars ± SD).
Customer Reviews Writing Reviews
Recent Advances
Drug Development Progress- English Name：
CD22
- Category：
- Approved Drugs：
2 Details
- Drugs in Clinical Trials：
73 Details
- Highest Development Stage：
Approved
Contact Us
Drug Candidate Licensing
